Showing Results for: “type 1 diabetes”

Children with early-onset type 1 diabetes (T1D) and poor glycemic control have slower growth of areas in the brain associated with mild cognitive deficits compared to children without diabetes, according to the study, “ADA Presidents' Select Abstract: Type 1 Diabetes and the Developing Brain—A Longitudinal Study of Brain Growth by the Diabetes Research in Children Network (DirecNet),” presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions® at the Moscone Convention Center in San Francisco. The study found that children with early-onset T1D have mild but

Pancreatic beta cells that do not produce sufficient insulin in people with type 2 diabetes (T2D) are not permanently damaged during the early stages of the disease and can be restored to normal function through the removal of excess fat in the cells, according to a study entitled “Remission of Type 2 Diabetes for Two Years Is Associated with Full Recovery of Beta-Cell Functional Mass in the Diabetes Remission Clinical Trial (DiRECT)” presented today at the American Diabetes Association’s® (ADA’s) 79th Scientific Sessions®. More than one-third (36%) of the participants who took part in an

The American Heart Association and the American Diabetes Association expand landmark Know Diabetes by Heart™ collaboration with Spanish campaign American Heart Association and American Diabetes Association aims to increase awareness and action among Spanish language-dominant people with type 2 diabetes to underscore the link between type 2 diabetes and heart disease and stroke. The announcement comes during Hispanic Heritage Month (September 15 – October 15). The Spanish-language campaign, found at DiabetesdeCorazon.org , is an extension of the American Heart Association and the American

NIDDK study continues to look at possible factors that lead to the development of the diseases in children New results and information surrounding potential “triggers” of the autoimmune process leading to type 1 diabetes (T1D) and how they interact with genetic factors in children at-risk for developing the disease were highlighted in the “Update from the TEDDY Study” symposium today at the American Diabetes Association’s® (ADA’s) 80th Virtual Scientific Sessions. Similar evidence for celiac disease is also being accumulated through the large international study program. The data The

Findings Reveal Efficacy of Novel Inhaler to Improve Glycemic Control for Patients with Type 1 Diabetes Today, findings from INHALE-3, a pivotal trial examining the use of inhaled insulin in adults with type 1 diabetes (T1D), were announced, highlighting the potential of an alternative insulin solution to enhance diabetes management. The results were presented as a symposium at the 84th Scientific Sessions of the American Diabetes Association® (ADA) in Orlando, FL. Type 1 diabetes affects 11.6% of the American population and millions of individuals globally , requiring ongoing insulin therapy

American Heart Association ® and American Diabetes Association ® reveal results of Know Diabetes by Heart ™ survey and share practical tips for staying on track with health goals through the holiday season Nearly half (49%) of people living with type 2 diabetes said managing their condition during a typical fall and winter holiday season is more difficult than other times of the year, according to a new survey for the American Heart Association and American Diabetes Association. The online survey of more than 1,000 U.S. adults 45 and older completed by real-time market research platform

National program establishes early care management, technology innovation and large health system engagement as a strategic priority for supporting the 34 million U.S. individuals living with diabetes The American Diabetes Association ® (ADA) and Renalytix (NASDAQ: RNLX) (LSE: RENX) announced today a joint program to improve overall kidney health in patients with type 2 diabetes (T2D) in the United States, which is expected to grow to 60 million individuals by 2060. The program intends to drive early detection and risk informed care delivery to delay disease progression, reduce dialysis starts

International Consensus Offers Guidance for Monitoring Autoantibody Positive Individuals in Early-Stage Type 1 Diabetes Data Shows Continuous Glucose Monitoring Helps Classify Patient Risk of Type 1 Diabetes New developments for early risk monitoring of Type 1 Diabetes (T1D) were presented as part of the American Diabetes Association’s® (ADA) 84th Scientific Sessions in Orlando, FL. An international consensus provided insights into how health care professionals can improve patient care for individuals with autoantibodies in early stage type 1 diabetes and new research highlighted the benefits

The first sub-analysis of renal data from the Dapagliflozin Effect on Cardiovascular Events Thrombolysis In Myocardial Infarction (DECLARE-TIMI 58) trial indicates that dapagliflozin, an oral sodium glucose cotransporter 2 (SGLT2) inhibitor, reduced the progression of kidney disease or renal death in patients with type 2 diabetes (T2D). The initial results from the trial, the first cardiovascular outcome study to enroll a large cohort of patients with diabetes risk factors for Atherosclerotic Cardiovascular Disease (ASCVD) and a large number of patients with diabetes with known ASCVD, were

The American Heart Association and the American Diabetes Association share inspiration from patients and need-to-know information from experts As emerging science around COVID-19 highlights elevated danger for people with diabetes, heart disease and stroke 1 , the American Heart Association and the American Diabetes Association urge people living with type 2 diabetes and/or cardiovascular disease to manage their conditions and look for unique opportunities to double-down on their health goals during the pandemic. Brandon Lewis of Dallas lives with diabetes, and now is dealing with being at